IVMED yields 285714.29% · JNJ yields 2.13%● Live data
📍 IVMED pulled ahead of the other in Year 1
Combined, IVMED + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IVMED + JNJ for your $10,000?
Whitebeard Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.
Full IVMED Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.